Patent ID: 8026260

Claim:
A compound represented by the following structural Formula I: wherein: Ring B is heteroaryl or aryl; R 1 is selected from hydrogen, C 1 -C 7 alkyl, C 1 -C 7 haloalkyl, C 1 -C 7 hydroxyalkyl, C 1 -C 7 alkenyl, C 1 -C 7 alkynyl, or L 2 -R 2 , wherein R 2 is substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, L 2 is selected from a bond or C 1 -C 4 alkylene; R 3 is OH, SH or NH 2 ; R 4 is selected from hydrogen, OH, NH 2 , nitro, CN, amide, carboxyl, C 1 -C 7 alkoxy, C 1 -C 7 alkyl, C 1 -C 7 haloalkyl, C 1 -C 7 haloalkyloxy, C 1 -C 7 hydroxyalkyl, C 1 -C 7 alkenyl, C 1 -C 7 alkyl-C(═O)O—, C 1 -C 7 alkyl-O—C(═O)—, C 1 -C 7 alkyl-C(═O)—, C 1 -C 7 alkynyl, halo group, hydroxyalkoxy, —NHSO 2 , —SO 2 NH, C 1 -C 7 alkyl-NHSO 2 —, C 1 -C 7 alkyl-SO 2 NH—, C 1 -C 7 alkylsulfonyl, C 1 -C 7 alkylamino, di(C 1 -C 7 )alkylamino, C 1 -C 7 acylamino, amino-C 1 -C 7 alkyl, C 1 -C 7 alkylthio, perfluoro-C 1 -C 7 alkyl, perfluoro-C 1 -C 7 alkyloxy; R 5 is selected from hydrogen, C 1 -C 10 alkyl, cycloalkyl, aryl or heterocyclyl, each of which is optionally substituted; R 13 is selected from hydrogen or halo; L 1 is a bond or (CH 2 ) r , ethenyl or cyclopropyl, wherein r is 1 or 2; X 1 is selected from the group consisting of a covalent bond, L 3 -M 1 -L 2 -M 1 -L 3 , and L 2 -M 2 -L 2 wherein: L 2 or L 3 , at each occurrence, is independently selected from the group consisting of a chemical bond, C 1 -C 4 -alkyl, C 1 -C 4 -alkyl-(NH)—C 1 -C 4 -alkyl, C 1 -C 4 -alkyl-(S)—C 1 -C 4 -alkyl, and C 1 -C 4 -alkyl-(O)—C 1 -C 4 -alkyl, each of the alkyl is optionally substituted, provided that L 2 is not a chemical bond when X 1 is L 3 -M 1 -L 2 -M 1 -L 3 ; M 1 , at each occurrence, is independently selected from the group consisting of —O—, —N(R 11 )—, —S—, —S(O)—, S(O) 2 —, —S(O) 2 N(R 11 )—, —N(R 11 )—S(O) 2 —, —C(O)—, —C(O)O—, —OC(O)—, —C(O)—N(R 11 ), —N(R 11 )—C(O)—, —C(S)—N(R 11 ), —N(R 11 )—C(S)—, —N(R 11 )—C(O)—O—, —O—C(O)—N(R 11 )—, —N(R 11 )—C(O)—N(R 11 )—, —N(R 11 )—C(S)—O—, —O—C(S)—N(R 11 )—, —N(R 11 )—C(S)—N(R 11 )—, R 11 is selected from the group consisting of hydrogen, C 1 -C 6 -alkyl, aryl, aralkyl, C(O)R 12 or C 0 -C 6 alkyl-heterocyclyl, wherein the alkyl moieties are optionally substituted with —OH, —NH 2 , —N(H)CH 3 , —N(CH 3 ) 2 , or halo, wherein R 12 is an optionally substituted C 1 -C 4 alkyl, perfluoro-C 1 -C 4 -alkyl, phenyl or heterocyclic; M 2 is selected from the group consisting of M 1 or heterocyclic, either of which rings optionally is substituted; Y is N or CR 13 ; t is 1, 2, 3 or 4; and Provided that when R 3 is NH 2 , Y is CR 13 , R 13 is H, L 1 is CH 2 , Ring B is imidazolyl, X 1 is a bond, R 5 is hydrogen, t is 1, R 4 is methyl, then R 1 is not hydrogen; or a stereoisomer or pharmaceutically acceptable salt thereof.